Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 3/20 | 0.62 |
| ▸ | SOAT2 | O75908 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 4/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | UBE2M | P61081 | 1/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9844078 | 0.91 | SOAT1 (0.56) | SOAT1SOAT2SMN1; SMN2KMT2ALMNA | |
| SCHEMBL13328398 | 0.90 | SOAT2 (0.55) | SOAT1SOAT2SMN1; SMN2KMT2ALMNA | |
| SCHEMBL9844229 | 0.87 | POLB (0.53) | SOAT1SOAT2SMN1; SMN2KMT2ALMNA | |
| SCHEMBL2147650 | 0.87 | KMT2A (0.65) | SOAT1SOAT2SMN1; SMN2KMT2ALMNA | |
| SCHEMBL11143056 | 0.85 | ALDH1A1 (0.58) | SOAT1SOAT2SMN1; SMN2KMT2ALMNA | |
| SCHEMBL9681145 | 0.84 | SOAT2 (0.56) | SOAT1SOAT2SMN1; SMN2KMT2ALMNA | |
| SCHEMBL9680211 | 0.83 | SOAT2 (0.52) | SOAT1SOAT2SMN1; SMN2KMT2ALMNA | |
| SCHEMBL9679656 | 0.82 | SOAT2 (0.60) | SOAT1SOAT2SMN1; SMN2KMT2ALMNA | |
| SCHEMBL9679390 | 0.81 | ALDH1A1 (0.58) | SOAT1SOAT2SMN1; SMN2KMT2ALMNA | |
| SCHEMBL9844236 | 0.81 | SMN1; SMN2 (0.57) | SOAT1SOAT2SMN1; SMN2KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0433662-A2 | Acat inhibitors | WARNER-LAMBERT COMPANY (US) | 1991-06-26 | — | — | EP | claimed |
| US-20160271137-A1 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS | UNIV PRINCETON (US) | 2016-09-22 | — | — | US | disclosed |
| US-20160271137-A1 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS | UNIV PRINCETON (US) | 2016-09-22 | — | — | US | disclosed |
| US-9168269-B2 | Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-10-27 | — | — | US | disclosed |
| US-9168269-B2 | Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-virals | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-10-27 | — | — | US | disclosed |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | KOYUNCU EMRE (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | KOYUNCU EMRE (US) | 2015-05-21 | — | — | US | disclosed |
| US-20130190381-A1 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190381-A1 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012139028-A2 | ANTI-VIRAL COMBINATION THERAPY | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-10-11 | — | — | WO | disclosed |
| WO-2011103516-A2 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2011-08-25 | — | — | WO | disclosed |
| EP-0433662-A2 | Acat inhibitors | WARNER-LAMBERT COMPANY (US) | 1991-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160271137-A1 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS | FASN, PLIN1, PLIN3 | SOAT1 117/4885SOAT2 105/4885SMN1; SMN2 4652/4885 |
| US-20130190381-A1 | INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALS | FASN, PLIN1, PLIN3 | SOAT1 117/4885SOAT2 105/4885SMN1; SMN2 4652/4885 |
| US-20150139949-A1 | ANTI-VIRAL COMBINATION THERAPY | HAVCR2, MAVS, ZC3HAV1 | SOAT1 1223/4885SOAT2 1598/4885SMN1; SMN2 4448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.